comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 23:00:23 - browse：76494

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure

leisure time

WSS

Shifting the focus from loneliness to social health

The Pandemic Treaty must support building strong health systems

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Cord blood banking comes at a high cost to babies

Ultragenyx gene therapy for rare liver ailment succeeds in late

Intellia reports positive results for its CRISPR

leisure time

comprehensive

leisure time

Supreme Court strikes down use of affirmative action

NIH documents show early flaws of $1.6 billion long Covid program

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Hepatitis C has a cure — but many Americans still lack access to it

When prostate cancer spreads, where it goes matters

DIEP, the 'gold standard' of breast reconstruction, is under threat

Woman returns to dialysis after doctors remove transplanted pig kidney

How one medical school became remarkably diverse

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

focus

Letters to First Opinion on caregivers, digital health, and more

See how much Covid

How to increase colonoscopy rates? Looks like an AI can help

Letters to First Opinion on caregivers, digital health, and more

Data integrity in scientific journals requires "effort" by publishers, institutions

ASCO: Palliative care found as helpful given virtually as in person

hotspot

focus

leisure time

entertainment